AMD highlights from ASRS: Positive real-world faricimab data, gene therapy and more
The American Society of Retina Specialists annual meeting featured study results and research in age-related macular degeneration.
In one presentation, a large ongoing real-world study of faricimab showed positive results in patients with wet AMD over 9 months. Another explored the high burden of geographic atrophy on patients and caregivers.
Check out Healio’s AMD-related coverage from the ASRS meeting below.
Burden of geographic atrophy high on patients, caregivers
In the U.S. and Canada, the burden of geographic atrophy on patients and caregivers is “substantial and multifaceted.”
“The incidence and burden of geographic atrophy due to dry macular degeneration are expected to rise globally, yet there is limited research on the patient and caregiver experience,” Sophie J. Bakri, MD, said. Read more.
VIDEO: Faricimab shows positive real-world results for wet AMD over 9 months
Theodore Leng, MD, FACS, discusses results of the FARETINA-AMD study investigating faricimab for wet age-related macular degeneration. Watch here.
Phase 2 results encouraging for ABBV-RGX-314 gene therapy in neovascular AMD
The phase 2 AAVIATE study showed safety and efficacy of ABBV-RGX-314 gene therapy in the treatment of neovascular age-related macular degeneration, with potential for sustained outcomes with a one-time in-office injection. Read more.
VIDEO: Opthea presents update on sozinibercept for wet AMD
Megan Baldwin, PhD, provides an update on OPT-302, now called sozinibercept, for the treatment of neovascular age-related macular degeneration. Watch here.
PULSAR trial shows efficacy of aflibercept 8 mg in wet AMD with long treatment intervals
The PULSAR trial in wet age-related macular degeneration demonstrated that aflibercept 8 mg administered every 12 or 16 weeks is noninferior in vision gains compared with aflibercept 2 mg every 8 weeks. Read more.